The prognosis biomarkers based on m6A-related lncRNAs for myeloid leukemia patients

BACKGROUND: Chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) are two common malignant disorders in leukemia. Although potent drugs are emerging, CML and AML may still relapse after the drug treatment is stopped. N6-methyladenosine (m6A) and lncRNAs play certain roles in the occurrence...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Li-Rong, Lin, Zhu-Ying, Hao, Qing-Gang, Li, Tian-Tian, Zhu, Yun, Teng, Zhao-Wei, Zhang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739709/
https://www.ncbi.nlm.nih.gov/pubmed/34996458
http://dx.doi.org/10.1186/s12935-021-02428-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739709/
https://www.ncbi.nlm.nih.gov/pubmed/34996458
http://dx.doi.org/10.1186/s12935-021-02428-3

Ejemplares similares